Qiagen NV (0RLT)
London Exchange · UK · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 41.23 |
|---|---|
| 52-week range | 27.42 – 47.18 |
| Return, 1 month / 3 months | +7.3% / +15.1% |
| Return, 1 year / 3 years | +1.4% / +8.2% |
| Trend | Uptrend |
| RSI (14) | 65 |
| Volatility (1 year) | 34.4% |
| Worst drawdown (1 year) | -40.9% |
| Average daily value traded | 6.20M EUR |
| Dividend yield | 5.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Qiagen is a life-sciences and molecular diagnostics company that supplies sample-preparation kits, assays and automated instruments for handling and analysing genetic material. Its products help laboratories extract and purify DNA and RNA and run molecular tests. Customers include clinical diagnostic labs, pharmaceutical and biotechnology researchers, applied-testing laboratories and academic institutions. The company is based in the Netherlands and operates internationally, serving research and healthcare markets around the world.
Qiagen NV trades under the code 0RLT on the London Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 3 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Qiagen NV (0RLT) trades on the London Exchange in UK. It last closed at EUR 41.23 on 19 October 2026.
Its price-based Market X-Ray is 59 out of 100 (a fair price profile), ranking 1,384 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 1.4% and over the last three months it rose 15.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 70 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 13.0% | ||
| From 52-week high | -11.4% | ||
| Momentum | 66 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 15.1% | ||
| 6-month return | 18.1% | ||
| 12-month return, skipping the last month | -5.5% | ||
| Stability (higher is calmer) | 41 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 34.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -40.9% | ||
| Liquidity | 70 · Fair | Moderate trading activity. | |
| Average daily value traded | 6.20M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 48 · Weak | Dividend is small or irregular. | |
| Dividend yield | 5.5% | ||
| Years with dividends | 3 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.2% |
|---|---|
| 1 month | +7.3% |
| 3 months | +15.1% |
| 6 months | +18.1% |
| 1 year | +1.4% |
| 3 years | +8.2% |
| 5 years | – |
Signals
| 50-day / 200-day average | 38.28 / 36.49 |
|---|---|
| Golden / death cross (60 days) | Golden, 25 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.12 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 6 Jul 2026 | EUR 0.3066 |
| 7 Jan 2026 | EUR 1.9590 |
| 1 Jul 2025 | EUR 0.2123 |
| 28 Jan 2025 | EUR 1.2087 |
| 30 Jan 2024 | EUR 1.1458 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.